Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-20T03:45:18.928Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme

Published online by Cambridge University Press:  29 June 2007

L. Deuñas ,
V. Alcantud ,
F. Alvarez ,
J. Arteaga ,
A. Benítez ,
M. Bopuza ,
L. Carniege ,
B. Cartaya ,
C. Comas  and
R. Cotayo
...Show all authors
L. Deuñas
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
V. Alcantud
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
F. Alvarez
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
J. Arteaga
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
A. Benítez
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
M. Bopuza
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
L. Carniege
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
B. Cartaya
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
C. Comas
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
R. Cotayo
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
H. Escobar
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
H. Fernández
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
M. Fernández
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
R. Fernández
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
M. García
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
N. Iznaga
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
F. la O
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
J Márquez
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
D. Nordet
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
J. Pérez
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
J. Quintero
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
A. Redonavich
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
M. Robeleco
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
H. Rodríguez
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
P. Ruíz
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
R. Seijas
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
E. Villavicencio
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
D. Viera
Affiliation:
Otorhinolaryngology Services of Hospitals throughout Cuba
F. Damas
Affiliation:
The Ministry of Public Health, Havana, Cuba
P. López-Saura
Affiliation:
Centre for Biological Research, Havana, Cuba
S. Haglund
Affiliation:
Department of Otorhinolaryngology, Stockholm Southern Hospital, Stockholm, Sweden
H. Strander*
Affiliation:
Department of Oncology (Radiumhemmet), Karolinska Hospital, Radiumhemmet, Stockholm, Sweden.
*
Address for correspondence: Hans Strander, M.D., Ass. Professor, Radiumhemmet, Karolinska Hospital, S-17176 Stockholm, Sweden.
Get access Rights & Permissions [Opens in a new window]

Abstract

Laryngeal papillomatosis is one of the first diseases where interferon (IFN) was found to be effective. In 1983, a programme for the treatment of all such cases started in Cuba. Up to December 1991, 125 patients (92 children, 33 adults) have been treated: 102 with leucocyte IFN-α, 12 with recombinant IFN-α-2b, and 11 have received both preparations. Case management consisted of surgical removal of the lesions followed by an IFN schedule starting with 105 IU/kg of weight in children or 6 × 106 IU in adults, i.m. daily. The dose was progressively reduced, as long as no relapses occurred. At the end of the one-year schedule the doses were reduced to 5 × 104 IU/kg in children or 3 × 106 IU in adults, weekly. If there was a relapse, it was removed surgically and the patient returned to a higher dose level. Most cases (89; 71 per cent) have not relapsed after the treatment; 60 of them have been followed for more than three years. In those with relapses, the frequency of recurrence decreased in all but four patients. The treatment seemed to be more effective if initiated less than three months after the disease onset. The tracheostomy could be removed in five out of seven patients who needed it before the IFN treatment and was necessary in only three new cases during IFN treatment. In two of these, decannulation was possible later on. In a total of 14 patients relapses persisted after several cycles of IFN treatment. They were considered resistant to such treatment. No severe side effects were reported. The most frequent ones were fever, drowsiness, increased bronchial secretion, chills and headache. The establishment of this programme has maintained the disease under control in Cuba.

Keywords

Interferon-αLaryngeal neoplasmsPapilloma
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 111 , Issue 2 , February 1997 , pp. 134 - 140
Copyright
Copyright © JLO (1984) Limited 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cantell, K., Hirvonen, S., Kauppinen, H. H., Myllyla, G. (1981a) Production of interferon in human leukocytes from normal donors with the use of Sendai virus. In Methods in Enzymology Vol. 78, (Pestka, S., ed.), Academic Press, New York. pp 29–38.Google Scholar
Cantell, K., Hirvonen, S. (1981b) Preparation and assay of Sendai virus. In Methods in Enzymology Vol. 78, (Pestka, S., ed), Academic Press. New York, pp 299–300.Google Scholar
Cantell, K., Hirvonen, S., Koistinen, V. (1981c) Partial purification of human leukocyte interferon on a large scale. In Methods in Enzymology Vol. 78, (Pestka, S., ed.), Academic Press, New York. pp 499–504.Google Scholar
Cole, R. R., Myer, C. M. III, Cotton, R. T. (1989) Tracheostomy in children with recurrent respiratory papillomatosis. Head and Neck Surgery 11: 226–230.Google ScholarPubMed
Dueñas, L., National OtoRhinoLaryngology Group, LópezSaura, P. (1993) Use of interferon α in laryngeal papillomatosis: eight years of the national program in Cuba. Journal of Interferon Research 13 (Supp. 1): S192.Google Scholar
Galloway, D. A., McDougall, J. K. (1989) Human papillomaviruses and carcinomas. Advances in Virus Research 37: 125–171.Google Scholar
Goebel, U., Arnold, W., Wahn, V., Freuner, J., Jurgens, H., Cantell, K. (1981) Comparison of human fibroblast and leucocyte interferon in the treatment of severe laryngeal papillomatosis in children. European Journal of Paediatrics 137: 175–176.CrossRefGoogle Scholar
Goepfert, H., Sessions, R. B., Gutterman, J. U., Canair, H., Dichtel, W. J., Sulek, M. (1982) Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Annals of Otology, Rhinology and Laryngology 91: 431–436.CrossRefGoogle ScholarPubMed
Haglund, S., Lundqvist, P. G., Cantell, K., Strander, H. (1981) Interferon therapy in juvenile laryngeal papillomatosis. Archives of Otolaryngology, Head and Neck Surgery 107: 327–332.Google Scholar
Healy, G. B., Gelber, R. D., Trowbridge, A. L., Grundfast, K. M., Ruben, R. J., Price, K. N. (1988) Treatment of recurrent respiratory papillomatosis with human leukocyte interferon: results of a multicenter randomized clinical trial. New England Journal of Medicine 319: 401–407.Google Scholar
Herrera, L., de la Fuente, J., Quiñones, Y., Padrón, G., Agraz, A., Vega, J. L., Pérez, L., Silva, A., Santizo, C., Alvarez, R. (1989) Biological productions by recombinant DNA technology in Cuba. In Developments in Biological Standardisation Vol. 70, S. Karger, Basel, pp 257–269.Google Scholar
Holinger, P. H., Tohston, K. C., Arison, G. C. (1950) Papilloma of the larynx: a review of 109 cases with a preliminary report of aureomycin therapy. Annals of Otolaryngology 59: 547–564.Google Scholar
Kleinsasser, O. (1988) Viruses, juvenile papilloma and laryngeal carcinoma. In Tumors of the Larynx and Hypopharynx George Thieme Verlag, Stuttgart, pp. 20–21.Google Scholar
Krajina, Z., Lenarcic-Cepelja, I., Jusic, R., Mazuran, D., Vranesic, D., Stavjenic, A. (1989) Juvenile papillomatosis of the larynx. Lijecnicki Vjesnik (Zagreb) 111: 419–423.Google ScholarPubMed
Leventhal, B. G., Kashima, H. K., Weck, P. W., Mounts, P., Whisnant, J. K., Clark, K. L., Cohen, S., Dedo, H. H., Donovan, D. J., Fearon, B. W., Gardiner, L. J., Lusk, R. P., Muntz, H. R., Richardson, M. A., Singleton, G. T., Yonkers, A. J., Wold, D. (1988) Randomized surgical adjuvant trial of interferon alpha-n1 in recurrent papillomatosis. Archives of Otolaryngology, Head and Neck Surgery 114: 1163–1169.Google Scholar
Leventhal, B. G., Kashima, H. K., Mounts, P., Thurmond, L., Chapman, S., Buckley, S., Wold, D., and the Papilloma Study Group (1991) Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alpha-n1. New England Journal of Medicine 325: 613–617.Google Scholar
Limonta, M. de J. (1983) Estado actual de las investigaciones en el uso del interferón en papilomatosis laríngea en Cuba y otros países del mundo. Revista Cubana de Investigaciones Biomédicas 2: 35–38.Google Scholar
Mattot, M., Ninane, J., Hamoir, M., Moulin, D., Mustin, V., Vermylen, C., Cornu, G. (1990) Combined CO2 laser and alpha recombinant interferon treatment in five children with juvenile laryngeal papillomatosis. Acta Clinica Belga 45: 158–163.CrossRefGoogle ScholarPubMed
McCabe, B. F., Clark, K. F. (1983) Interferon and laryngeal papillomatosis. The Iowa experience. Annals of Otology, Rhinology and Laryngology 92: 2–7.CrossRefGoogle ScholarPubMed
Mounts, P., Shah, K. V. (1984) Respiratory papillomatosis: etiological relation to genital tract Papillomaviruses. In Progress in Medical Virology Vol. 29, (Melnick, J. L., ed), S Karger AG, New York, pp 90–114.Google Scholar
Pfister, H. (1984) Biology and biochemistry of papillomaviruses. Reviews of Physiology, Biochemistry and Pharmacology 99: 111–181.Google Scholar
Ponce, M., Limonta, M. J., Paz, N., Uriarte, H., Selman, E., Escobar, R. (1983) Uso del interferon leucocitario en papilomatosis laríngea en Cuba. In Memorias del ler Seminario Cubano sobre Interferon. Instituto de Cooperación Iberoamericana, Madrid-La Habana. pp 409–413.Google Scholar
Quiney, R. E., Hall, D., Croft, C. B. (1989) Laryngeal papillomatosis: analysis of 113 patients. Clinical Otolaryngology 14: 217–225.Google Scholar
Redonavich, A., Escobar, H., Ramirez, V., Limonta, M. J., Carniege, L., Pérez, J., Fernández, M., Iznaga, N., Comas, C., Fernández, H., Garcia, M., Seijas, R., Márquez, A, Ponce, M., Rodríguez, H. (1986) Uso de interferon leucocitario humano en la papilomatosis laríngea. Programa Nacional. In Memorias del II Seminario Cubano sobre Interferon. Instituto de Cooperación Iberoamericana, Madrid - La Habana. pp 229–233.Google Scholar
Redonavich, A., Escobar, H., López-Saura, P., Limonta, M., Carniege, L., Pérez, J., Fernández, H., Comas, C., Fernández, M., Márquez, J., Garcia, M., Iznaga, M., Seijas, R., Benitez, A. (1989) Use of human leukocyte interferon in papillomatosis. National Program. Journal of Interferon Research 9: S262.Google Scholar
Robbins, S. L. (1988) Patologia Estructural y Funcional, 3rd Edition, Nueva Editorial Interamericana, México, pp 753–754.Google Scholar
Steinberg, B. M., Meade, R., Kalinowski, S., Abramson, A. L. (1990) Abnormal differentiation of human papillomavirus induced laryngeal papillomas. Archives of Otolaryngology, Head and Neck Surgery 116: 1167–1175.Google Scholar
Strander, H. (1989) The action of interferons on virus-associated human neoplasms. Cancer Surveys 8: 755–792.Google Scholar
Strong, M. S., Vaughn, C. W., Healy, G. B. (1976) Recurrent respiratory papillomatosis. Management with the CO2 laser. Annals of Otology, Rhinology and Laryngology 85: 508–516.CrossRefGoogle ScholarPubMed
Tucker, H. M. H. (1987) Laryngeal neoplasia. In The Larynx Thieme Medical Publishers Inc., New York, pp 47–51.Google Scholar
von Wussow, P., Borden, E. (1989) Antibodies to interferons in patients: defining their significance. Journal of Interferon Research 9 (Suppl. 1): pp 75.Google Scholar
Zur Hausen, H. (1977) Humanpathogene Papillomaviren. Arzneimittel Forschung/Drug Research 27: 212–215.Google Scholar